← Leaderboards
Chun-Wei David Chen
Beckman Research Institute/City Of Hope
$8,071,175
Attributed
$8,071,175
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,071,175 · 6
By mechanism
R01$3,742,690 · 2
R37$2,755,844 · 1
R00$747,000 · 1
P01$517,525 · 1
K99$308,116 · 1
Top collaborators
No co-investigators on record.
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Jianjun Chen$21,393,583
- Guido Marcucci$19,718,636
- Lihua Elizabeth Budde$959,566
- Alexey V. Danilov$3,278,847
- Rui Su$1,365,394
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsGene ExpressionLeukemiaProgramsAcute LeukemiaMll GeneEpigenetic ProcessLysineAchievementGene RearrangementClustered Regularly Interspaced Short Palindromic RepeatsCancer TypeHistone H3MediatingPre-ClinicalNovel TherapeuticsOncogenesGenome-WideGene Expression RegulationPublishingResponseClinically RelevantChromatinSirt1 Gene
Grant awards (24)
CRISPR Tiling$517,525
P01 · FY2025 · CA · contact PI
Combinational Targeting the Feed-forward Epigenetic Circuitry in Mixed Lineage Leukemia$402,600
R37 · FY2025 · CA · contact PI
Mechanism and therapeutic opportunities of targeting the Tudor domain$375,715
R01 · FY2025 · CA · contact PI
Mechanism and therapeutic opportunities of targeting the Tudor domain$135,566
R01 · FY2025 · CA · contact PI
Mechanism and therapeutic opportunities of targeting the Tudor domain$485,717
R01 · FY2024 · CA · contact PI
Combinational Targeting the Feed-forward Epigenetic Circuitry in Mixed Lineage Leukemia$382,469
R37 · FY2024 · CA · contact PI
Mechanism and therapeutic opportunities of targeting the Tudor domain$510,917
R01 · FY2023 · CA · contact PI
Role of BAZ2A in MLL-r leukemia and therapeutic response$387,823
R01 · FY2023 · CA · contact PI
Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia$387,823
R37 · FY2023 · CA · contact PI
Role of BAZ2A in MLL-r leukemia and therapeutic response$395,738
R01 · FY2022 · CA · contact PI
Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia$395,738
R37 · FY2022 · CA · contact PI
Role of BAZ2A in MLL-r leukemia and therapeutic response$527,738
R01 · FY2021 · CA · contact PI
Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia$395,738
R37 · FY2021 · CA · contact PI
Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia$395,738
R37 · FY2020 · CA · contact PI
Role of BAZ2A in MLL-r leukemia and therapeutic response$395,738
R01 · FY2020 · CA · contact PI
Integrative Analyses of Saturation CRISPR Protein Scan$132,000
R01 · FY2020 · CA · contact PI
Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia$395,738
R37 · FY2019 · CA · contact PI
Role of BAZ2A in MLL-r leukemia and therapeutic response$395,738
R01 · FY2019 · CA · contact PI
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia$249,000
R00 · FY2019 · CA · contact PI
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia$249,000
R00 · FY2018 · CA · contact PI
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia$249,000
R00 · FY2017 · CA · contact PI
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia$154,058
K99 · FY2017 · CA · contact PI
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia$123,922
K99 · FY2016 · CA · contact PI
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia$30,136
K99 · FY2016 · CA · contact PI